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University Hospital Birmingham NHS Foundation Trust, Birmingham, UKSee Article, pages 1106–1114Autoimmune hepatitis (AIH) is a classical autoimmune liver
disease that has characteristic features of autoimmunity. It is
more commonly seen in women, strongly associated with vari-
ants in the major histocompatibility complex region and usually
responsive to immunosuppression. Although the aetiology is still
unknown the development of the disease involves a loss of
immunological self-tolerance to liver antigens resulting in a T cell
mediated destruction of hepatocytes [1]. The majority of AIH
patients require lifelong immunosuppression to maintain remis-
sion and the treatment for AIH still relies on corticosteroids and
azathioprine, which were ﬁrst introduced more than 25 years
ago [2]. In recent years it has been suggested that one of the fac-
tors that predisposes to autoimmune disease is an imbalance
between effector and regulatory arms of the immune system
[3,4]. Evidence of this comes not only from clinical studies but
also from animal studies in which defects in immune regulation
and a lack of functional regulatory T cells (Tregs) is associated
with the development of autoimmunity including autoimmune
hepatitis. However, it is less clear whether the defect in patients
with AIH is due to a failure of regulatory cell recruitment or func-
tion, or whether regulatory cells are simply overwhelmed by
dominant effector cell responses. The article by Taubert and col-
leagues in this edition of the Journal of Hepatology sheds more
light on this debate. They conducted a correlative study using
immunohistochemistry and ﬂow cytometry to quantify the rela-
tive proportions of effector cells, regulatory T cells and B cells in
the liver and blood of patients with type1 AIH. Consistent with
other studies they reported that intrahepatic Tregs are enriched
in untreated type1 AIH but that their numbers fall in response
to therapy. The authors suggest that this effect of therapy might
explain the high relapse rates seen after discontinuation of
immunosuppression in AIH and speculate that therapies thatJournal of Hepatology 20
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Open access under CC BY-NC-ND license.increase or preserve intrahepatic immunoregulation might be
better suited for the long-term control of AIH.
Lymphocytes comprise around 25% of intrahepatic immune
cells and include effector CD4 T cells, cytotoxic T cells, B cells,
invariant iNKT, and MAIT cells [5]. Regulatory networks particu-
larly intrahepatic CD4+CD25highCD127lowFOXP3+ regulatory T
cells control the effector responses. The intrahepatic frequency
of these cells varies from 1% to 5% of the lymphocyte population
in most chronic liver diseases [6] and is associated with a reversal
of the CD4/CD8 ratio in the liver comparedwith blood [7]. In auto-
immune hepatitis, CD4 T cells dominate in the early stage of the
disease, particularly Th1 cells [8]. Subsequently, T helper cells
recruit cytotoxic CD8 T cells leading to higher CD8 T cell frequen-
cies and possibly more aggressive cytotoxic T cell mediated
destruction of hepatocytes as the disease progresses as described
by Taubert and colleagues [9].
Staining for the FOXP3 transcription factor, the master regula-
tor of Treg differentiation and function has been widely used to
quantify CD4 Tregs in tissues [10]. However, FOXP3 is also
expressed transiently during T cell activation and in some other
lymphocyte subsets, potentially reducing the reliability of single
colour immunohistochemistry to quantify Tregs in hepatic
inﬂammation [6,11]. The current report partially overcomes this
by using double immunohistochemistry. However, in the
inﬂamed environment some Tregs may display lineage plasticity
and express both FOXP3 and the Th1 transcription factor TBet
[12] and high local levels of TGF-b and retinoic acid may generate
induced Tregs [13,14]. A more detailed phenotypic analysis of
freshly isolated intra-hepatic Tregs with multi-colour ﬂow
cytometry would answer these questions particularly if this
includes the TSDR methylation status, which correlates closely
with stability and function of thymic derived Tregs [15].
AIH ﬂares are characterized by high frequencies of both Tregs
and effector T cells (Teffs) in the inﬂamed liver [8,9] (Fig. 1). Now
Taubert and colleagues show that patients reaching biochemical
remission have higher intrahepatic Treg/Teff and Treg/B cell
ratios compared to those who fail to respond. This suggests that
Tregs are important in gaining and maintaining remission. The
ﬁnding that intrahepatic Tregs decrease during therapy is novel
and particularly interesting and could explain the high relapse
rates after discontinuation of immunosuppression. The authors’14 vol. 61 j 973–975
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Fig. 1. Intrahepatic effector lymphocytes include TBet transcription factor expressing Th1 cells, RORc transcription factor expressing Th17 cells, CD8 T cells, and
immunoglobulin G (IgG) secreting plasma cells are involved in hepatic inﬂammation (lobular hepatitis and interface hepatitis) in AIH. FOXP3+ regulatory T cells
(Tregs) suppress effector lymphocyte proliferation and cytokine secretion to control ongoing hepatitis. Intrahepatic Tregs express CD4, CD25, CTLA-4, CD45RA, liver homing
chemokine receptor CXCR3 and secrete IL-10 and TGF-b. The hepatic microenvironment is enriched with pro-inﬂammatory cytokines such as IL-6, IL-12, TNF, IFN-c, and
professional antigen presenting dendritic cells. Survival, differentiation and apoptosis of both effector lymphocytes and regulatory T cells are dependent on the intrahepatic
microenvironment, stellate cells, biliary epithelial cells and dendritic cells. The balance of T effector/B cells vs. Tregs generally dictates the outcome of autoimmune
hepatitis.
Editorialdata, showing that Tregs are more susceptible to particular forms
of immunosuppression, suggest we should consider drugs that
more speciﬁcally suppress effector cell responses. These observa-
tions are relevant for future therapy with infused Tregs and
would suggest that Treg infusions will be most effective if used
at induction or instead of maintaining immunosuppression. The
current study reports that steroid and azathioprine therapy has
a greater effect on intrahepatic Tregs compared with T effector
cells [1,9]. An important immunosuppressive mechanism of
action of prednisolone/glucocorticoid is the inhibition of IL2 gene
expression and two other commonly used immunosuppressive
drugs, cyclosporine and tacrolimus; also reduce IL-2 production974 Journal of Hepatology 201[16]. Tregs are highly dependent on IL-2 and this may explain
the particular susceptibility of Tregs to treatment in the present
study. Thus, it may be logical to use immunosuppressive drugs
that preserve IL-2 mediated signalling in AIH.
We have previously reported similar frequencies of intrahe-
patic effector and regulatory lymphocytes in liver tissue removed
at transplantation from patients with autoimmune hepatitis [6]
but the present study is the ﬁrst to describe this in steroid-naïve
patients. The consistent frequencies of intrahepatic Tregs show
that there is no failure of Treg recruitment to the liver in AIH,
and suggest it is the balance of Tregs and effector cells that will
dictate the outcome. It is thus important to understand the4 vol. 61 j 973–975
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factors within the hepatic microenvironment that determine dif-
ferential survival or activation of Tregs and effector cells (Fig. 1).
A further observation in the present paper was that the fre-
quency of intra-portal B cells correlates with levels of serum
IgG suggesting that the elevated IgG levels that are characteristic
of active AIH may be a consequence of local intrahepatic produc-
tion. More research is required to understand the functional con-
sequences of local B cell activation in the liver and the nature of
the IgG secreting cells. The fact that IgG secretion falls on ritux-
imab therapy despite the fact that CD20 is not expressed on
plasma cells suggests that IgG autoantibodies may be secreted
by memory B cells within inﬂammatory niches in tissue consis-
tent with the ﬁndings of the present study [17].
Another important conclusion from the present study is that
studies of Tregs in blood may not reﬂect what happens in tissues.
Studies have reported different ﬁndings regarding the frequency
and function of Tregs in the peripheral blood of patients with
autoimmune hepatitis [18–20], which emphasizes the importance
of studying intrahepatic Tregs and not over-interpreting ﬁndings
from blood. Finally, analysis of the makeup of hepatic inﬁltrates
in AIH may provide useful to predict outcome and response to
therapy as well as helping to predict which patients can have
immunosuppression withdrawn without a high risk of relapse.
In conclusion, the present study provides more evidence on
the important role of intrahepatic Tregs vs. effector T cells and
B cells in autoimmune hepatitis. A detailed study of Tregs in
the liver tissues and how inﬂammation effects their local survival
and function will provide closer understanding of Tregs in auto-
immune hepatitis (Fig. 1). Functional rather than phenotypic
studies are required to gain the necessary insights into the path-
ogenesis but they are difﬁcult to perform. Correlation of immuno-
phenotypic data with clinical data is helpful as suggested in the
current study. Immunoregulatory mechanisms in the human
liver are more complicated than previously thought and under-
standing these aspects will allow us to develop more speciﬁc
therapy in AIH that gets away from blanket immunosuppression.Financial support
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